This interactive, case-based OncoBlast activity equips oncology professionals with practical strategies for optimizing treatment decisions in multiple myeloma. Participants will apply evidence-based guidelines to manage toxicities, select appropriate therapies based on patient- and disease-specific factors, and understand the evolving role of bispecific antibodies, CAR-T therapy, and maintenance regimens in clinical practice.
Course Accreditations
Course Summary
| Events Starts | Events Ends |
|---|---|
| 1/1/2025 | 12/31/2025 |
Faculty
Rahul Banerjee (MD, FACP)
Dr. Rahul Banerjee, MD, FACP, is an Assistant Professor in the Division of Medical Oncology at the University of Washington (Seattle, WA); he also holds a faculty appointment at the Fred Hutchinson Cancer Center. He previously completed his hematology/oncology fellowship and advanced BMT/CAR-T fellowship at the University of California San Francisco (San Francisco, CA). His clinical interests are in multiple myeloma, AL amyloidosis, and CAR-T therapy. His research interests are in toxicity management, digital health, and the patient experience.
Disclosure
Financial relationships Yes, I have had a financial relationship with an ineligible company within the past 24 months. Financial relationships: Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Adaptive Biotech Topic: Consulting Attribution: Self Type of financial relationship: Independent contractor Ineligible company: BMS Topic: Consulting Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Caribou Biosciences Topic: Consulting Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Genentech/Roche Topic: Consulting Attribution: Self Type of financial relationship: Independent contractor Ineligible company: GSK Topic: Consulting Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Karyopharm Topic: Consulting Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Legend Biotech Topic: Consulting Attribution: Self Type of financial relationship: Independent contractor Ineligible company: JNJ / Janssen Topic: Consulting Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Pfizer Topic: Consulting Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Sanofi Topic: Consulting Attribution: Self Type of financial relationship: Independent contractor Ineligible company: SparkCures Topic: Consulting Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: Abbvie Topic: Research Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: BMS Topic: Research Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: JNJ / Janssen Topic: Research Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: Novartis Topic: Research Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: Pack Health Topic: Research Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: Prothena Topic: Research Attribution: Self Type of financial relationship: Grant Or Contract Ineligible company: Sanofi Topic: Research
Danai Dima (MD)
Danai Dima, MD is a board-certified internist and hematologist-oncologist currently completing her fellowship at the Cleveland Clinic Foundation, where she has served as a leader in curriculum development and quality improvement for inpatient hematology-oncology services. She earned her medical degree summa cum laude from the National and Kapodistrian University of Athens, Greece, where she ranked in the top 1% of her class and received multiple academic awards. Dr. Dima completed her internal medicine residency at Tufts Medical Center in Boston, where she was recognized as a Primary Care Hero and actively contributed to medical student education and mock code training. Her research has earned multiple Abstract Achievement Awards from the American Society of Hematology, and she remains an engaged member of several national and international professional societies, including ASH, ASCO, and ISTH.
Disclosure
Financial relationships No, I have not had a financial relationship with an ineligible company within the past 24 months.
- Cancer care professionals
- Practicing medical oncologists/hematologists
- Radiation oncologists
- Pathologists
- Medical oncology and hematology fellows
- Oncology nurses
- Nurse practitioners
- Physician assistants
- Pharmacists
Target Audience
- Select appropriate therapeutic regimens in newly diagnosed and relapsed/refractory multiple myeloma based on patient fitness, cytogenetics, and prior therapies.
- Identify and manage treatment-related toxicities associated with IMiDs, proteasome inhibitors, bispecific antibodies, and CAR-T therapies.
- Apply risk-adapted approaches to maintenance therapy and timing of advanced therapies, including autologous transplantation and BCMA-targeted treatments.
Learning Objectives
Upon successful completion of this educational activity, participants will be able to: